Date: 2019

1800 - 1930 UTC

1100-1230 PDT

1400-1530 EDT

1600-1730 Argentina time

Zoom Meeting Details

SNOMED Int'l Editorial Advisory group

Please join my meeting from your computer, tablet or smartphone:

Topic: SNOMED Editorial Advisory Group Conference Call

Time: Mar 19, 2019 1900 UTC; 1100 PDT

https://snomed.zoom.us/j/464312001

Attendees

Chair:

Jim Case

AG Members

Observers:

Apologies

Meeting Files

Meeting recording

The folder containing the meeting recordings is located here.

The recording for this meeting is located here.

Objectives

Obtain consensus on agenda items
Provide resolution for outstanding issues

Discussion items

Item	Topic	Owner	Description	Discussion	Action
1	Call to order and role call Conflicts of Interest	JCA	GRE - Contractor to SI, Principal in TermMed	Start recording
	ECE Update	BGO	Gout secondary to drug treatment Secondary gout discussion Inactivation of secondary disorders.pptx Secondary diseases_SNOMED.xlsx Non-traumatic injuries Injury_damage_traumatic_nontraumatic.pptx	Injury discussion Damage and injury are often used synonymously ICD definition for injury is more specific to traumatic injuries Trauma is more of a process than a morphology Non-traumatic is difficult to define There is a gray area between traumatic and non-traumatic Is this a false dichotomy -what is the use case for making the distinction? What are we trying to distinguish? External causes? Suggestion to consider using DUE TO = Event as opposed to a pathological process There is not much difference in treatment base don whether traumatic or non-traumatic Consider using the mechanism of injury rather than trying to distinguish trauma vs. non-trauma Initial step WRT non-traumatic brain injury proposed to create intermediate primitive	Test the use of DUE TO = event to model traumatic events Bruce Goldberg Create a new primitive term "Non-traumatic injury" as a stop gap to address the obstacles to defining this notion Bruce Goldberg
	Substance role groups	TMO	Product role disposition Product role options Product role affected concepts	Five options discussed Concern expressed by KCA that ignoring option 4 is not based on correct representation and does not address the true issue. What should be modeled in the core? Most of the modeling of therapeutic roles should occur in extensions. Recommend that option 4 be reworded to state that it would be an evolutionary approach The main problem is that the core is currently not modularized so it is not possible to segregate these relationship outside of the core module. The secondary issue is that the association of clinical drug to the product roles is jurisdictionally dependent. Suggestion is that these associations be placed in a separate module	Test the potential for creation of a new attribute within a new International release module. This would be part of the International release, but could be excluded if desired (i.e. there is an extension replacement) - refer to MAG and TRF AGs for testing Test use of non-defining attribute for future movement towards modularization - requires tooling change? Maintain a role hierarchy without defined subtypes as part of the international release, except for those that can be identified as universally accepted, requiring national extensions to maintain differences. Use existing drug terminologies. Potential issues exist with leveraging the classifier for this.
	SNOMED CT Clinical Core	JCA	Background on proposed "SNOMED Clinical Core" Discussion on mechanism to identify content for the core	Continued to the April Business meeting	Jim Case to present new content strategy in detail at the April Business meeting
	Future meetings	JCA	Development of agenda topics for April Face-to-face meeting	Will be handled by email exchange